2018
DOI: 10.1039/c8ra00888d
|View full text |Cite
|
Sign up to set email alerts
|

The unequivocal preponderance of biocomputation in clinical virology

Abstract: Biocomputation in clinical virology.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
5
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 103 publications
0
5
0
Order By: Relevance
“…Computational virology is an emergent research field that takes advantage of the progress from molecular and structural biology, immunology, bioinformatics and related areas to foster the understanding of virus, their evolutionary dynamics in nature, infectivity, pathogenesis, cell/host-tropism, viral assembly and their molecular interactions in general (including how to predict epitopes, how to design specific neutralizing antibodies and basically any drug design & discovery related to viral infections) (Poveda-Cuevas et al, 2020;Ibrahim et al, 2018;Greber, 2019;Sharma et al, 2015;Sato et al, 2013;Backert and Kohlbacher, 2015;Chun et al, 2018;Viso et al, 2018). In particular, structural and interactive aspects can benefit from the solid foundations that computational molecular simulation methods such as Molecular Dynamics (MD) (Frenkel et al, 2001;Rapaport, 2004) and Monte Carlo (MC) (Frenkel et al, 2001;Binder, 1986) have achieved to probe the thermodynamic, dynamics and interactive properties of biomolecules in material science, food and pharma (see Refs.…”
Section: Theoretical Methodsmentioning
confidence: 99%
“…Computational virology is an emergent research field that takes advantage of the progress from molecular and structural biology, immunology, bioinformatics and related areas to foster the understanding of virus, their evolutionary dynamics in nature, infectivity, pathogenesis, cell/host-tropism, viral assembly and their molecular interactions in general (including how to predict epitopes, how to design specific neutralizing antibodies and basically any drug design & discovery related to viral infections) (Poveda-Cuevas et al, 2020;Ibrahim et al, 2018;Greber, 2019;Sharma et al, 2015;Sato et al, 2013;Backert and Kohlbacher, 2015;Chun et al, 2018;Viso et al, 2018). In particular, structural and interactive aspects can benefit from the solid foundations that computational molecular simulation methods such as Molecular Dynamics (MD) (Frenkel et al, 2001;Rapaport, 2004) and Monte Carlo (MC) (Frenkel et al, 2001;Binder, 1986) have achieved to probe the thermodynamic, dynamics and interactive properties of biomolecules in material science, food and pharma (see Refs.…”
Section: Theoretical Methodsmentioning
confidence: 99%
“…Computational virology is an emergent research field that takes advantage of the progress from molecular and structural biology, immunology, bioinformatics and related areas to foster the understanding of virus, their evolutionary dynamics in nature, infectivity, pathogenesis, cell/hosttropism, viral assembly and their molecular interactions in general (including how to predict epitopes, how to design specific neutralizing antibodies and basically any drug design & discovery related to viral infections). [27][28][29][30][31][32][33][34] In particular, structural and interactive aspects can benefit from the solid foundations that computational molecular simulation methods such as Molecular Dynamics (MD) 35,36 and Monte Carlo (MC) 35,37 have achieved to probe the thermodynamic, dynamics and interactive properties of biomolecules in material science, food and pharma (see refs. 38,39 for reviews).…”
Section: Theoretical Methodsmentioning
confidence: 99%
“…The major advantage of peptide-based vaccines is that their development is both safe and inexpensive in comparison to conventional techniques of vaccine production [8,9]. Interestingly, PVX-410, P10s-PADRE and TPIV200 are some of the chimeric peptide-based vaccines for TNBC that are currently in clinical phase trials.…”
Section: Introductionmentioning
confidence: 99%